MICS and phaco on a par?

Article

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss.

Microincision cataract surgery (MICS) and phacoemulsification result in similar visual outcomes and early endothelial cell loss, according to a study published in the November/December 2006 issue of the European Journal of Ophthalmology.

Michal Wilczynski and colleagues from the Medical University of Lodz, Poland prospectively compared 40 eyes of 40 patients undergoing surgery. Half of the subjects underwent MICS and the other half underwent standard phaco with implantation of a foldable intraocular lens (IOL).

At ten days follow-up, the two groups had statistically similar mean best corrected visual acuity (BCVA); 0.94 in the MICS group and 0.9 in the phaco group (p>0.05). Both groups showed significant decreases in postoperative endothelial cell density and the losses were also statistically similar. The MICS patients lost an average of 9.5% of cells for a mean postoperative cell density of 2,235 cells/mm2. Patients in the phaco group lost an average of 7.6% of cells for a mean postoperative cell density of 2,079 cells/mm2 (p>0.05).

The authors of the study concluded that MICS and phacoemulsification result in statistically similar early endothelial cell losses, in addition to similar visual outcomes.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.